AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen
AbbVie’s latest upbeat read on its Q2 numbers included a sour note that is likely to put another one of Biogen’s top pipeline projects under a cloud.
The pharma giant said today that they shut down a Phase II trial for the anti-tau drug ABBV-8E12 after investigators determined that the data indicated it was useless to push ahead on a neurodegenerative study for progressive supranuclear palsy. The drug and the class are also being studied in Alzheimer’s, a field that has been blighted by near-constant failure over the past 20 years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.